ArticleThoracic cancer2022

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.

Yaping Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.